Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis-Reference-Cited by-同舟云学术

Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis

Published:2022-12-16 Issue:5 Volume:68 Page:2115-2122
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Tahata Yuki,Sakamori Ryotaro,Yamada Ryoko,Kodama Takahiro,Hikita Hayato,Hagiwara Hideki,Oshita Masahide,Imai Yasuharu,Hiramatsu Naoki,Mita Eiji,Kaneko Akira,Miyazaki Masanori,Ohkawa Kazuyoshi,Hijioka Taizo,Fukui Hiroyuki,Ito Toshifumi,Yamamoto Keiji,Doi Yoshinori,Yoshida Yuichi,Yamada Yukinori,Yakushijin Takayuki,Tatsumi Tomohide,Takehara Tetsuo^ORCID,

Funder

Gilead Sciences

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s10620-022-07629-y.pdf

Reference26 articles.

1. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 2016;64:405–414.

2. Ioannou GN, Beste LA, Chang MF et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs National Health Care System. Gastroenterology 2016;151:457–471.

3. Tahata Y, Sakamori R, Urabe A et al. Liver fibrosis is associated with corrected QT prolongation during ledipasvir/sofosbuvir treatment for patients with chronic hepatitis C. Hepatol Commun 2018;2:884–892.

4. Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: from interferon to direct-acting antiviral. Glob Health Med 2021;3:321–334.

5. Tahata Y, Hikita H, Mochida S et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol 2022;57:120–132.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response;Scientific Reports;2024-05-13

2. The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL);Scientific Reports;2024-02-03